CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole

Alimentary Pharmacology and Therapeutics

Volumn 14, Issue 10, 2000, Pages 1259-1266

  Adachi, K ^a   Katsube, T ^a   Kawamura, A ^a   Takashima, T ^a   Yuki, M ^a   Amano, K ^a   Ishihara, S ^a   Fukuda, R ^a   Watanabe, M ^a   Kinoshita, Y ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; LANSOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ADULT; ARTICLE; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; GENOTYPE; HELICOBACTER PYLORI; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; STOMACH ACID SECRETION; STOMACH PH;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; BENZIMIDAZOLES; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; GASTRIC ACID; GASTRIC ACIDITY DETERMINATION; GENOTYPE; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROTON PUMPS;

EID: 0033793888     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2000.00840.x     Document Type: Article

References (47)

1. Optimizing acid suppression for treatment of acid-related diseases
2. Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease
3. Proton pump inhibitors and acid-related diseases
4. Review article: The pharmacology of rabeprazole
5. Combined gastric and oesophageal 24-hour pH monitoring and oesophageal manometry in patients with reflux disease, resistant to treatment with omeprazole
6. Persistent acid secretion during omeprazole therapy: A study of gastric acid profiles in patients demonstrating failure of omeprazole therapy
7. Prolonged ambulatory pH monitoring in patients with persistent gastroesophageal reflux disease symptoms: Testing while on therapy identifies the need for more aggressive anti-reflux therapy
8. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole
9. Review article: The development of atrophic gastritis-Helicobacter pylori and the effects of acid suppressive therapy
10. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer
11. Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole
12. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole
13. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole
14. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs
15. Identification of the human P450 enzymes involved in lansoprazole metabolism
16. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4'-hydroxylation status
17. Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor
18. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans
19. Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man
20. Mephenytoin hydroxylation deficiency in Caucasians: Frequency of a new oxidative drug metabolism polymorphism
21. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans
22. Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese
23. Genotyping of S-mephenytoin 4'-hydroxylation in an extended Japanese population
24. Review article: Cytochrome P450 and the metabolism of proton pump inhibitors - Emphasis on rabeprazole
25. Helicobacter pylori infection
26. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease
27. Eradication of Helicobacter pylori: An objective assessment of current therapies
28. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4'-hydroxylation phenotype status
29. Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4'-hydroxylation phenotype and genotype
30. Helicobacter pylori infection has no role in the pathogenesis of reflux esophagitis
31. Decreased prevalence of Helicobacter pylori infection in gastroesophageal reflux disease
32. Helicobacter pylori infection inhibits reflux esophagitis by inducing atrophic gastritis
33. Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents
34. Intragastric acidity as a predictor of the success of Helicobacter pylori eradication: A study in peptic ulcer patients with omeprazole and amoxicillin
35. Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice
36. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer
37. Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers
38. Phenotyping polymorphic drug metabolism in the French Caucasian population
39. S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin
40. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese
41. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin
42. Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics
43. Genetic polymorphism of S-mephenytoin 4'-hydroxylation in African-Americans
44. Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population
45. Comparison of Helicobacter pylori infection between Fukuoka, Japan and Chinju
46. Helicobacter pylori infection and mode of transmission in a population at high risk of stomach cancer
47. Helicobacter pylori infection in a randomly selected population, healthy volunteers, and patients with gastric ulcer and gastric adenocarcinoma. A seroprevalence study in Taiwan